This is topic CDC finally recognizing infections as cause of chronic illness! New paper. in forum Medical Questions at LymeNet Flash.


To visit this topic, use this URL:
https://flash.lymenet.org/ubb/ultimatebb.php/topic/1/45625

Posted by mycoplasma1 (Member # 6377) on :
 
See:

http://www.cdc.gov/ncidod/EID/vol12no07/06-0037.htm

Finally!
 
Posted by mycoplasma1 (Member # 6377) on :
 
Sorry Cave! Saw you posted this already.
 
Posted by lou (Member # 81) on :
 
I think their definition of chronic may differ from ours. They mean it resists eradication by the immune system alone. We mean that it can resist eradication by antibiotics.

So, we can hope for some enlightenment, but not quite ready to schedule the celebration.
 
Posted by minimonkey (Member # 8693) on :
 
Still, this *is* progress it seems. Of course, I really question the motives of the CDC, given the history of poo-poo-ing chronic illness as factitious, etc. I wonder why the sudden willingness to disclose this???

Am I just paranoid????
 
Posted by David95928 (Member # 3521) on :
 
Groucho Marx said "Even paranoids can have real enemies."
 
Posted by welcome (Member # 7953) on :
 
quote:
Originally posted by minimonkey:
Still, this *is* progress it seems. Of course, I really question the motives of the CDC, given the history of poo-poo-ing chronic illness as factitious, etc. I wonder why the sudden willingness to disclose this???

Am I just paranoid????

Just because you're paranoid doesn't mean they AREN'T out to get you!

[Big Grin]

Or like I am wont to say, "It's not whether you're paranoid, it's whether you're paranoid enough!"
 
Posted by BugBit (Member # 7829) on :
 
Well, for one thing, the paragraph about Human Papiloma Virus is completely out of place and context.
To me the article appears to be dis-information on a number of other topics, including the new HPV vaccine. See article below:

You'll love this... note the financial save for the drug company AND the fact that they agreed to promote sexual abstinence as part of the package. It's almost impossible to believe!




FDA panel endorses cervical cancer vaccine

By THOMAS GINSBERG

Philadelphia Inquirer

A vaccine to prevent cervical cancer won endorsement yesterday by a federal medical panel, a key step toward approval for use by millions of girls and young women perhaps by July.

Gardasil, which would be manufactured in the Philadelphia suburbs by Merck & Co. Inc., still needs final approval by the U.S. Food and Drug Administration, but the agency typically takes its panels' advice.

Merck predicted Gardasil would prevent about 350,000 cases yearly of cervical cancer worldwide within two decades, when all girls vaccinated as infants will have entered high-risk adulthood. An estimated 3,700 women in the United States, and 300,000 worldwide, die from cervical cancer in a year.

Gardasil also might help alleviate Merck's own financial ailments from its recall and lawsuits concerning the pain reliever Vioxx and loss of patent-protected sales of the cholesterol drug Zocor. Wall Street analysts have predicted that Gardasil sales will far surpass $1 billion a year by 2010, high for a vaccine.

"I love the world of vaccines," said Rick Haupt, executive director of medical affairs at Merck's vaccine division. "We're in the business of vaccines for now and the future, and this is a very important step."

After a daylong meeting in Gaithersburg, Md., the FDA's Vaccines and Related Biological Products Advisory Committee unanimously recommended Gardasil for use in women and girls ages 9 to 26. Merck has estimated that 374 million people a year eventually could be candidates for the vaccination.

Gardasil is designed to be administered in three low-dose shots over six months. It works by preventing infection from two types of human papillomavirus, or HPV, that have been shown to cause 70 percent of cervical cancers. It is most effective in virgins or females previously unexposed to HPV, an extremely common virus thought to be present in 20 million people in any of its many strains, most of which resolve on their own.

Gardasil also blocks infection by two other HPV types linked primarily to genital warts.

A rival drugmaker, GlaxoSmithKline P.L.C., with U.S. headquarters partly in Philadelphia, is working on its own HPV vaccine targeting a slightly different set of virus types. But its Cervarix is still in development and may not be submitted for FDA approval until next year, the company has said.

Merck promised the FDA reviewers it would market Gardasil with the message that sexual abstinence and Pap smears are the only sure ways to prevent HPV infection and catch cancers. Its marketing campaign might include supporting sexual-abstinence programs, Merck has said.

"This vaccine is not a replacement for cervical-cancer screening," said Eliav Barr, head of Merck's biological clinical research in West Point.

Side effects include fever and occasional soreness at the injection site. Merck reported five instances in which women taking Gardasil later had children with birth defects. But it argued, and FDA reviewers agreed, that there was probably no connection to Gardasil because of the variation in defects and pregnancy periods.

A parade of health advocates - many of them disclosing they had received Merck grants - rose to urge the FDA advisers to endorse Gardasil.

"The FDA has an opportunity to move toward a world without cervical cancer," said Martha Nolan, vice president of the Society for Women's Health Research.

Backed by the groups, Merck asked the committee to endorse vaccination of boys ages 9 to 15, too. Urging them not to wait for studies to end, it said evidence showed that Gardasil could prevent some male cancers and might slow the spread of sexually transmitted HPV.

"By delaying three-plus years, we could have an additional 100,000 [cancer] cases that could have otherwise been avoided," Barr told the committee.

But panel members did not vote on the request, calling the idea compelling but unproven.

If the vaccine is approved by FDA officials, as expected, the next hurdle for Merck would come June 29, when vaccine experts at the Centers for Disease Control and Prevention are scheduled to consider whether to include Gardasil on its list of recommended vaccinations for children in the United States.

State and local officials are not obligated to follow the CDC, but usually do, and sometimes even go further by requiring certain vaccines for school enrollment - a huge boost for drugmakers.

Some groups initially concerned that the HPV vaccines would encourage sexual activity said they supported the vaccine, as long as schools did not require it as a condition of enrollment.

Merck, which has taken great pains to assuage the groups, declined to say whether it thinks Gardasil should be mandatory, but does support mandatory vaccinations in general.

"We are considering all kinds of interventions that could implement this vaccine, and under consideration are ways we can support states to drive implementation," Haupt said.

Wall Street analysts have projected that Gardasil sales could reach $140 million this year, $670 million next year, and $1.9 billion by 2010.

One analyst, Steve Scala of Cowen & Co. L.L.C., cautioned that the Gardasil sales projections might be high, and said GlaxoSmithKline's vaccine still could prove to be better. Nonetheless, Scala called Gardasil a likely blockbuster drug that could provide Merck with a needed boost.

Merck's global headquarters are in Whitehouse Station, N.J., but much of the Gardasil work would be done by Merck's marketing and vaccine operations centered at West Point and employing 10,000 to 12,000 across Montgomery County.

The complex is the largest in the 60,000-employee company. It largely was spared from severe cuts in Merck's restructuring plan initiated last year.
 
Posted by cutie (Member # 8468) on :
 
Too late for me...I already HAVE HPV! My gyno said she would let my immune system take care of it. I wonder if my immune response is even capable with my measely little 17 NK cells!
 


© 1993-2020 The Lyme Disease Network of New Jersey, Inc.
All Rights Reserved.
Use of the LymeNet Site is subject to the Terms and Conditions.

Powered by UBB.classic™ 6.7.3